Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Savara, a biopharmaceutical company, has appointed Nevan Elam, Curt Bilby and Matthew Dennis to its board of directors.
Subscribe to our email newsletter
Mr Elam has been appointed to fill a seat previously held by Cory Berkland. Mr Elam is a former member of the executive management team of Nektar Therapeutics where he served as senior vice president, head of the pulmonary business unit.
Dr Bilby is president and CEO of Terapio, a developer of protein-based therapeutics. Dr Bilby is a four-time biotechnology CEO with more than 20 years of entrepreneurial leadership and executive management experience – both domestically and in Europe. Dr Bilby also serves as chairman of BioAustin. Mr Dennis is currently senior director of International Equities, Invesco AIM.
Rob Neville, executive chairman of the board of Savara, said: “We are honored to have these new members join the board of directors. Their experience, including Mr Elam’s proven track record in the pulmonary drug delivery space, will provide an essential perspective as we respond to increasing interest in our platform NanoCluster technology.”